EP Patent

EP3694863A1 — Crystalline form of lorlatinib free base hydrate

Assigned to Pfizer Inc · Expires 2020-08-19 · 6y expired

What this patent protects

The present invention relates to a crystalline form of free (10R) -7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-free hydrate base 8.4- (metheno) pyrazolo [4,3-h] [2,5,11] benzoxadiazacycloetetradecine-3-carbonitrile (lorlatinib) (form 24). The invention al…

USPTO Abstract

The present invention relates to a crystalline form of free (10R) -7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-free hydrate base 8.4- (metheno) pyrazolo [4,3-h] [2,5,11] benzoxadiazacycloetetradecine-3-carbonitrile (lorlatinib) (form 24). The invention also relates to pharmaceutical compositions comprising Form 24 and methods of using it and such compositions in the treatment of abnormal cell growth, including cancer, in a mammal.

Drugs covered by this patent

Patent Metadata

Patent number
EP3694863A1
Jurisdiction
EP
Classification
—
Expires
2020-08-19
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.